Karin Sundfeldt

ORCID: 0000-0002-7135-3132 · 30 papers in corpus
observational 2026
Journal of translational medicine ·doi:10.1186/s12967-026-07879-8

BACKGROUND: To enable immunotherapy for ovarian cancers, precision targets for immune priming as well as patient stratification approaches are required. The tumor microenvironment in particularly the rare subtypes of low-grade serous, mucin…

rct 2026
Acta obstetricia et gynecologica Scandinavica ·doi:10.1111/aogs.70247

INTRODUCTION: Opportunistic salpingectomy during benign hysterectomy with ovarian preservation has become a preventive approach to epithelial ovarian cancer, particularly high-grade serous carcinoma, given evidence that it originates in the…

other 2026
BMJ open ·doi:10.1136/bmjopen-2025-111928

INTRODUCTION: Endometriosis is a chronic, inflammatory and oestrogen-dependent disease frequently causing infertility. Assisted reproductive technologies (ART) are often required to achieve pregnancy, especially in women with advanced endom…

qualitative 2026
Women's health (London, England) ·doi:10.1177/17455057261455291

BackgroundChronic pain is a common symptom of endometriosis with significant negative impact on physical and social activities. Patients perceive that healthcare professionals lack knowledge about the condition, and that available treatment…

diagnostic-accuracy 2025
Communications medicine ·doi:10.1038/s43856-025-00945-0

BACKGROUND: Ovarian cancer has the highest mortality of all gynecological cancers and surgery is commonly used as final diagnostic. Available literature indicates that women with benign tumors could often be conservatively managed, but accu…

other 2025
Gynecologic Oncology ·doi:10.1016/j.ygyno.2025.05.013

OBJECTIVE: Many epithelial ovarian cancer (EOC) risk factors relate to sex hormones. The association between these factors and the expression of androgen receptor (AR), estrogen receptor-α (ER), and progesterone receptor (PR) in tumors is u…

other 2024
Human Reproduction ·doi:10.1093/humrep/deae043

STUDY QUESTION: Can the alleged association between ovarian endometriosis and ovarian carcinoma be substantiated by genetic analysis of endometriosis diagnosed prior to the onset of the carcinoma? SUMMARY ANSWER: The data suggest that ovar…

diagnostic-accuracy 2024
Scientific reports ·doi:10.1038/s41598-024-68249-2

Ovarian cancer is the 8th most common cancer among women and has a 5-year survival of only 30-50%. While the survival is close to 90% for stage I tumours it is only 20% for stage IV. Current biomarkers are not sensitive nor specific enough,…

rct 2024
The Lancet regional health. Europe ·doi:10.1016/j.lanepe.2024.101026

BACKGROUND: Opportunistic salpingectomy to reduce ovarian cancer incidence has become increasingly common despite the lack of randomised trials investigating its safety. In SALSTER, we tested whether salpingectomy for laparoscopic sterilisa…

diagnostic-accuracy 2024
iScience ·doi:10.1016/j.isci.2024.109001

Early detection is key for increased survival in ovarian cancer, but no general screening program exists today due to lack of biomarkers and overall cost versus benefit over traditional clinical methods. Here, we used dried cervico-vaginal …

observational 2023
The journal of pathology. Clinical research ·doi:10.1002/cjp2.311

Our objective was to test whether p53 expression status is associated with survival for women diagnosed with the most common ovarian carcinoma histotypes (high-grade serous carcinoma [HGSC], endometrioid carcinoma [EC], and clear cell carci…

other 2023
BMJ open ·doi:10.1136/bmjopen-2022-071246

INTRODUCTION: Salpingectomy is currently suggested as an alternative to tubal ligation for sterilisation. Precursor lesions of ovarian carcinoma can be found in the fallopian tubes; thus, salpingectomy could possibly reduce the incidence. M…

diagnostic-accuracy 2022
Communications medicine ·doi:10.1038/s43856-022-00193-6

BACKGROUND: Ovarian cancer is the eighth most common cancer among women and due to late detection prognosis is poor with an overall 5-year survival of 30-50%. Novel biomarkers are needed to reduce diagnostic surgery and enable detection of …

diagnostic-accuracy 2022
International journal of cancer ·doi:10.1002/ijc.34111

Our study reports the discovery and evaluation of nanoparticle aided sensitive assays for glycovariants of MUC16 and MUC1 in a unique collection of paired ovarian cyst fluids and serum samples obtained at or prior to surgery for ovarian car…

diagnostic-accuracy 2022
Cancers ·doi:10.3390/cancers14071757

BACKGROUND: Ovarian cancer is the eighth most common cancer among women and has a 5-year survival of only 30-50%. The survival is close to 90% for patients in stage I but only 20% for patients in stage IV. The presently available biomarkers…

review 2021
Proteomes ·doi:10.3390/proteomes9020025

Despite recent technological advancements allowing the characterization of cancers at a molecular level along with biomarkers for cancer diagnosis, the management of ovarian cancers (OC) remains challenging. Proteins assume functions encode…

nonrandomized-trial 2021
Clinical chemistry and laboratory medicine ·doi:10.1515/cclm-2021-0510

OBJECTIVES: To evaluate the impact of different biologic, histopathologic and lifestyle factors on serum levels of human epididymis protein 4 (HE4) and Cancer antigen 125 (CA125) in the diagnostic work up of women with an ovarian cyst or pe…

review 2021
Journal of clinical medicine ·doi:10.3390/jcm10225397

During their lifespan, many women are exposed to pain in the pelvis in relation to menstruation and pregnancy. Such pelvic pain is often considered normal and inherently linked to being a woman, which in turn leads to insufficiently offered…

observational 2021
·doi:10.1101/2021.09.16.21262993

Abstract ARID1A (BAF250a) is a component of the SWI/SNF chromatin modifying complex, plays an important tumor suppressor role, and is considered prognostic in several malignancies. However, in ovarian carcinomas there are contradictory repo…

observational 2021
The Journal of Pathology ·doi:10.1002/path.5849

ARID1A (BAF250a) is a component of the SWI/SNF chromatin modifying complex, plays an important tumour suppressor role, and is considered prognostic in several malignancies. However, in ovarian carcinomas there are contradictory reports on i…

other 2020
Frontiers in oncology ·doi:10.3389/fonc.2020.561888

Ovarian carcinoma is a heterogeneous disease with distinct molecular and histological profiles, ranging from low grade atypia to highly aggressive tumors associated with a poor prognosis. In the present study, glycosphingolipids were isolat…

diagnostic-accuracy 2020
Journal of clinical medicine ·doi:10.3390/jcm9020299

Ovarian cancer is the most lethal gynecologic cancer. Pre-diagnostic testing lacks sensitivity and specificity, and surgery is often the only way to secure the diagnosis. Exploring new biomarkers is of great importance, but the rationale of…

other 2019
Trials ·doi:10.1186/s13063-018-3083-8
diagnostic-accuracy 2018
Clinical proteomics ·doi:10.1186/s12014-018-9216-y

BACKGROUND: Over 500,000 women worldwide are diagnosed with ovarian or endometrial cancer each year. We have used a two-step strategy to identify plasma proteins that could be used to improve the diagnosis of women with an indication of gyn…

diagnostic-accuracy 2018
Science translational medicine ·doi:10.1126/scitranslmed.aap8793

We report the detection of endometrial and ovarian cancers based on genetic analyses of DNA recovered from the fluids obtained during a routine Papanicolaou (Pap) test. The new test, called PapSEEK, incorporates assays for mutations in 18 g…